

ASX ANNOUNCEMENT

MARKET RELEASE

19 November 2024

Completion of Placement and Cleansing Notice

Artrya Limited (ASX:AYA), ('Artrya' or the 'Company'), a medical technology company focused on commercialising its patented AI platform that detects key coronary artery disease imaging markers, advises of the completion of the share placement announced to ASX on 12 November 2024 (**Placement**).

The Company advises of the issue today of the following securities in relation to the completion of the Placement:

- 11,904,762 ordinary fully paid shares issued at \$0.42 per share;
- 1,190,476 unlisted options exercisable at \$0.63 per option and expiring 19 November 2026 (Options) issued to the lead manager.

Petra Capital acted as sole lead manager and sole bookrunner to the Placement.

An Appendix 2A and Appendix 3G reflecting the issue of the abovementioned securities issued will follow this announcement. A cleansing notice with regards to the issue of the placement shares accompanies this announcement.

This announcement was approved by the Board.

For further information please contact:

Investor Enquiries:

Danny Younis
[+61 420 293 042](tel:+61420293042)
danny.younis@automicgroup.com.au

Media Relations:

Tristan Everett
+61 403 789 096
tristan.everett@automicgroup.com.au

About Artrya

Based in Perth, Australia, Artrya was founded in 2018 with operations starting in early 2019. The Company was listed on the Australian Securities Exchange (ASX: AYA) in 2021.

Artrya is an applied artificial intelligence healthcare company that works alongside clinicians to improve the diagnosis of coronary heart disease and develop a holistic overview of at-risk patients. The company has developed deep-learning algorithms pending regulatory submission for clearance and approval in the US that will serve to predict and prevent acute coronary events.

For more information, see www.artrya.com

ASX ANNOUNCEMENT

MARKET RELEASE

19 November 2024

SECONDARY TRADING NOTICE – NOTIFICATION PURSUANT TO PARAGRAPH 708A(5)(E) OF THE CORPORATIONS ACT 2001

Artrya Limited (ASX: AYA) (Artrya or the Company), a medical technology company focused on commercialising its patented AI platform that detects key coronary artery disease imaging markers, provides this notice in accordance with section 708A(5)(e) of the Corporations Act 2001 (Cth) (Corporations Act) in relation to an issue of 11,904,762 fully paid ordinary shares by Artrya on 19 November 2024 (Shares).

1. The Shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act.
2. As at the date of this notice, the Company has complied with the provisions of Chapter 2M of the Corporations Act as they apply to the Company and sections 674 and 674A of the Corporations Act.
3. As at the date of this notice, there is no excluded information (in accordance with the requirements of subsections 708A(7) and (8) of the Corporations Act.

Artrya Limited

Kevin Hart

Company Secretary

This announcement was approved by the Board.

For further information please contact:

Investors

Danny Younis

+61 420 293 042

danny.younis@automicgroup.com.au

Media

Tristan Everett

+61 403 789 096

tristan.everett@automicgroup.com.au

About Artrya

Based in Perth, Australia, Artrya was founded in 2018 with operations starting in early 2019. The Company was listed on the Australian Securities Exchange (ASX: AYA) in 2021.

Artrya is an applied artificial intelligence healthcare company that works alongside clinicians to improve the diagnosis of coronary heart disease and develop a holistic overview of at-risk patients. The company has developed deep-learning algorithms pending regulatory submission for clearance and approval in the US that will serve to predict and prevent acute coronary events.

For more information, see www.artrya.com